Pharmaceuticals, Biotechnology and Life Sciences
OptiBiotix Health, a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, finished first half of trading with sales of £351k, compared to the year 2022 sales of the same period, of £119k, which is a 195% increase over, the company said in its unaudited results for the six months ended 30 June 2023.
OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base, said Stephen O’Hara, CEO of OptiBiotix Wednesday in the half year financial report.
OptiBiotix Health will have its two abstracts presented at ProBiota 2017 in Berlin, which is taking place from February 1-3, 2017. ProBiota is the leading annual event for the global prebiotic, probiotic and the microbiota focused food and pharma industries.